Abstract
Background: Direct oral anticoagulants (DOACs) offer consistent and predictable anticoagulation, oral administration with good patient compliance and a good safety profile. Dabigatran - a direct thrombin inhibitor, apixaban and rivaroxaban - direct factor Xa inhibitors are now largely used for anticoagulation in patients with nonvalvular atrial fibrillation and in patients with venous thromboembolism. These agents have emerged as an expediential clinical choice in long-term anticoagulation for an increasing number of patients. Despite their advantages, concerns persist about a lack of rapid reversal agents in urgent clinical situations.
Methods: This review is focused on the pharmacology of nonspecific and target-specific reversal agents for DOACs-induced anticoagulation. A systemic review of preclinical and clinical studies published in peer-reviewed scientific journals was performed. Results and Conclusions: Fresh frozen plasma and coagulation factors concentrates might be considered in bleeding emergencies; however, there is a lack of larger studies confirming the efficacy of coagulation factors concentrates for the reversal of DOACs-induced anticoagulation, and a particular risk of coagulation factors concentrates-induced thrombosis. Recently, idarucizumab has been approved commercially for acute reversal of dabigatran in emergencies as a first target-specific reversal agent. Moreover, andexanet alpha and aripazine are being extensively studied in several phase II and III clinical studies. It is likely that more target-specific agents for reversal of DOACs-induced anticoagulation will be introduced to clinical practice in near future.Keywords: Dabigatran, DOACs-related bleeding, new oral anticoagulants reversal, idarucizumab, adnexanet alpha, aripazine.
Graphical Abstract
Current Drug Metabolism
Title:Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal
Volume: 18 Issue: 7
Author(s): Matej Samos*, Lucia Stanciakova, Ingrid Skornova, Tomas Bolek, Frantisek Kovar, Jan Stasko, Peter Galajda, Marian Mokan and Peter Kubisz
Affiliation:
- Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59 Martin,Slovakia
Keywords: Dabigatran, DOACs-related bleeding, new oral anticoagulants reversal, idarucizumab, adnexanet alpha, aripazine.
Abstract: Background: Direct oral anticoagulants (DOACs) offer consistent and predictable anticoagulation, oral administration with good patient compliance and a good safety profile. Dabigatran - a direct thrombin inhibitor, apixaban and rivaroxaban - direct factor Xa inhibitors are now largely used for anticoagulation in patients with nonvalvular atrial fibrillation and in patients with venous thromboembolism. These agents have emerged as an expediential clinical choice in long-term anticoagulation for an increasing number of patients. Despite their advantages, concerns persist about a lack of rapid reversal agents in urgent clinical situations.
Methods: This review is focused on the pharmacology of nonspecific and target-specific reversal agents for DOACs-induced anticoagulation. A systemic review of preclinical and clinical studies published in peer-reviewed scientific journals was performed. Results and Conclusions: Fresh frozen plasma and coagulation factors concentrates might be considered in bleeding emergencies; however, there is a lack of larger studies confirming the efficacy of coagulation factors concentrates for the reversal of DOACs-induced anticoagulation, and a particular risk of coagulation factors concentrates-induced thrombosis. Recently, idarucizumab has been approved commercially for acute reversal of dabigatran in emergencies as a first target-specific reversal agent. Moreover, andexanet alpha and aripazine are being extensively studied in several phase II and III clinical studies. It is likely that more target-specific agents for reversal of DOACs-induced anticoagulation will be introduced to clinical practice in near future.Export Options
About this article
Cite this article as:
Samos Matej *, Stanciakova Lucia , Skornova Ingrid , Bolek Tomas , Kovar Frantisek , Stasko Jan , Galajda Peter , Mokan Marian and Kubisz Peter , Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal, Current Drug Metabolism 2017; 18 (7) . https://dx.doi.org/10.2174/1389200218666170413155351
DOI https://dx.doi.org/10.2174/1389200218666170413155351 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Twin-to-Twin Transfusion Syndrome: From Placental Anastomoses to Long-Term Neurodevelopmental Outcome
Current Pediatric Reviews Endothelial Dysfunction, Impaired Endogenous Platelet Inhibition and Platelet Activation in Diabetes and Atherosclerosis
Current Vascular Pharmacology Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design Biomarkers Associated with Stroke Risk in Atrial Fibrillation
Current Medicinal Chemistry Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Non-transfusion Dependent Thalassemias: A Developing Country Perspective
Current Pediatric Reviews Discovery-Based Strategies for Studying Platelet Function
Mini-Reviews in Medicinal Chemistry Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology The Molecular Nature and Consequences of Lipoprotein (A)s Association with Platelets
Protein & Peptide Letters Chronic Thromboembolic Pulmonary Hypertension-Therapeutic Options
Current Respiratory Medicine Reviews Leptin Signaling in Blood Platelets as a Target for Therapeutic Intervention
Current Signal Transduction Therapy Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target
Current Vascular Pharmacology Recent Advances in Optimal Adjunctive Antithrombotic Therapy in STEMI Patients Undergoing Primary Angioplasty: An Overview
Current Vascular Pharmacology Catastrophic Antiphospholipid Syndrome: Lessons from the “CAPS Registry”
Current Rheumatology Reviews Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Recent Patents in Imaging of the Vulnerable Atherosclerotic Plaque: The Search for the Holy Grail
Recent Patents on Medical Imaging α2-Antiplasmin: Potential Therapeutic Roles in Fibrin Survival and Removal
Current Medicinal Chemistry - Cardiovascular & Hematological Agents G-protein Dependent Platelet Signaling - Perspectives for Therapy
Current Drug Targets Pharmacogenetics of Oral Anticoagulant Therapy
Current Pharmaceutical Design